PT  - JOURNAL ARTICLE
AU  - Ebinger, Joseph E.
AU  - Botwin, Gregory J.
AU  - Albert, Christine M.
AU  - Alotaibi, Mona
AU  - Arditi, Moshe
AU  - Berg, Anders H.
AU  - Binek, Aleksandra
AU  - Botting, Patrick
AU  - Fert-Bober, Justyna
AU  - Figueiredo, Jane C.
AU  - Grein, Jonathan D.
AU  - Hasan, Wohaib
AU  - Henglin, Mir
AU  - Hussain, Shehnaz K.
AU  - Jain, Mohit
AU  - Joung, Sandy
AU  - Karin, Michael
AU  - Kim, Elizabeth H.
AU  - Li, Dalin
AU  - Liu, Yunxian
AU  - Luong, Eric
AU  - McGovern, Dermot P.B.
AU  - Merchant, Akil
AU  - Merin, Noah
AU  - Miles, Peggy B.
AU  - Nguyen, Trevor-Trung
AU  - Raedschelders, Koen
AU  - Rashid, Mohamad A.
AU  - Riera, Celine E.
AU  - Riggs, Richard V.
AU  - Sharma, Sonia
AU  - Sobhani, Kimia
AU  - Sternbach, Sarah
AU  - Sun, Nancy
AU  - Tourtellotte, Warren G.
AU  - Eyk, Jennifer E. Van
AU  - Braun, Jonathan G.
AU  - Cheng, Susan
TI  - SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms
AID  - 10.1101/2020.08.02.20166876
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.02.20166876
4099  - http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166876.short
4100  - http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166876.full
AB  - Of individuals with SARS-CoV-2 IgG antibody testing performed, those who contemporaneously experienced a cluster of Covid-19 relevant symptoms in the 1-2 months preceding the antibody assay were more likely to test positive whereas those who experienced the symptom clustering in the prior 3-6 months were more likely to test negative. These findings suggest that antibodies likely wane over a period of months, particularly in relation to the timing of symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by Cedars Sinai Medical Center and the Erika J. Glazer Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study protocols were approved by the Cedars Sinai institutional review board and all participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from Cedars-Sinai Medical Center, upon reasonable request. The data are not publicly available due to the contents including information that could compromise research participant privacy/consent.